Poulter, Neil

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis

Writing Group for the CKD Prognosis Consortium, Appel, L. J., Grams, M., Woodward, M., Harris, K., Arima, H., Chalmers, J., Yatsuya, H., Tamakoshi, K., Li, Y., et al. (2023) · JAMA

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 396

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 390

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 363

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

for the ADVANCE Collaborative Group, Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M. E., Colagiuri, S., Fulcher, G., de Galan, B. E., Harrap, S., et al. (2012) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 358

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 343

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Poulter, N. R., Wedel, H., Dahlöf, B., Sever, P. S., Beevers, D. G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., et al. (2005) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 319

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 316

Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

CHARGE-Heart Failure Consortium, Surendran, P., EchoGen Consortium, METASTROKE Consortium, GIANT Consortium, EPIC-InterAct Consortium, Study, L. C., Wellcome Trust Case Control Consortium, Understanding Society Scientific Group, EPIC-CVD Consortium, et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyBlood Pressure and Hypertension Studies

Cited by 312

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial

for the ADVANCE Collaborative group, de Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D. E., Hackett, M., et al. (2009) · Diabetologia

Diabetes Treatment and ManagementDementia and Cognitive Impairment Research

Cited by 243

Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON

Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 240

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study

Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., et al. (2009) · European Heart Journal

Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension Studies

Cited by 239

Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk

Gupta, A. K., Nasothimiou, E. G., Chang, C. L., Sever, P. S., Dahlöf, B., & Poulter, N. R. (2011) · Journal of Hypertension

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 165

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

Prabhakaran, D., Anand, S., Watkins, D., Gaziano, T., Wu, Y., Mbanya, J. C., Nugent, R., Ajay, V. S., Afshin, A., Adler, A., et al. (2018) · The Lancet

Cardiovascular Health and Risk FactorsGlobal Public Health Policies and Epidemiology

Cited by 162

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 160

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial

Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 147

Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication

Gupta, A. K., Dahlof, B., Dobson, J., Sever, P. S., Wedel, H., Poulter, N. R., & on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators (2008) · Diabetes Care

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 146

Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure

Sharman, J. E., O’Brien, E., Alpert, B., Schutte, A. E., Delles, C., Hecht Olsen, M., Asmar, R., Atkins, N., Barbosa, E., Calhoun, D., et al. (2020) · Journal of Hypertension

Blood Pressure and Hypertension StudiesNon-Invasive Vital Sign Monitoring

Cited by 139

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial

McGuire, D. K., Busui, R. P., Deanfield, J., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N., Engelmann, M. D. M., Hovingh, G. K., et al. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 131

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial

Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Gupta, A., Mackay, J., Whitehouse, A., Godec, T., Collier, T., Pocock, S., Poulter, N., & Sever, P. (2018) · The Lancet

Blood Pressure and Hypertension StudiesLipoproteins and Cardiovascular Health

Cited by 119

Roadmap to Achieve 25% Hypertension Control in Africa by 2025

Dzudie, A., Rayner, B., Ojji, D., Schutte, A. E., Twagirumukiza, M., Damasceno, A., Ba, S. A., Kane, A., Kramoh, E., Anzouan Kacou, J. B., et al. (2018) · Global Heart

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 119

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 118